ClinicalTrials.gg

Program

dazukibart

Also written as “PF-06823859”, “Dazukibart” and “Anti-Beta Interferon (PF-06823859)”.

In Pfizer's pipeline, anti-IFN-β. Its studies are mostly in Dermatomyositis · Lupus Erythematosus, Systemic, led by Pfizer.

Furthest: phase 3, since Apr 27, 20237 company-led studies, 2 open or runningNext primary completion: Jul 29, 2030 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer72 open or runningphase 3since Apr 27, 2023May 6, 2016Jul 29, 2030phase 3 · NCT05895786
  • Named in Pfizer’s own pipeline as dazukibart PF-06823859, phase 3, as of Nov 3, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 6, 2016First study: phase 1 study in HealthyFirst studyNCT02766621 · 62 enrolled · United States
  2. Jun 5, 2017Phase 2 study in DermatomyositisNCT03181893 · 75 enrolled · United States, Germany, Hungary and more
  3. Aug 11, 2021Phase 1 study in HealthyNCT05037409 · 13 enrolled · Japan
  4. Dec 1, 2021Phase 2 study in DermatomyositisNCT05192200 · 24 enrolled · United States, Hungary, Poland and more
  5. Apr 27, 2023Phase 3 study in MyositisNCT05895786 · 318 planned · United States, Argentina, Bulgaria and more
  6. May 18, 2023Phase 2 study in Lupus Erythematosus, SystemicNCT05879718 · 8 enrolled · United States, Canada, Greece and more
  7. Oct 24, 2024Phase 3 study in DermatomyositisNCT06698796 · 211 planned · United States, Argentina, Bulgaria and more

Ahead

  1. Jul 29, 2030Primary completion: phase 3 study in MyositisNCT05895786
  2. Jul 29, 2031Primary completion: phase 3 study in DermatomyositisNCT06698796

TargetBeta

“anti-IFN-β”the company's pipeline, read by Claude · source

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06698796Dermatomyositis · United States, Argentina, Bulgaria and more3RecruitingJul 29, 2031211
NCT05879718Lupus Erythematosus, Systemic · United States, Canada, Greece and more2TerminatedJun 5, 20258
NCT05895786Myositis · United States, Argentina, Bulgaria and more3RecruitingJul 29, 2030318
NCT05192200Dermatomyositis · United States, Hungary, Poland and more2CompletedNov 20, 202324
NCT05037409Healthy · Japan1CompletedMar 27, 202213
NCT03181893Dermatomyositis · United States, Germany, Hungary and more2CompletedMay 27, 202275
NCT02766621Healthy · United States1CompletedAug 30, 201762

How it is read

Names in the registry

  • “PF-06823859”, 4 entries
  • “Dazukibart”, 1 entry
  • “Anti-Beta Interferon (PF-06823859)”, 1 entry
  • “PF-06823859 low”, 1 entry
  • “PF-06823859 high”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.